C5a, a therapeutic target in sepsis - PubMed (original) (raw)

Review

C5a, a therapeutic target in sepsis

Ren-Feng Guo et al. Recent Pat Antiinfect Drug Discov. 2006 Jan.

Abstract

The complement activation product, C5a, is a potent inflammatory peptide with a broad spectrum of biological functions. Plasma levels of C5a are increased in sepsis, accompanied by increased content of C5a receptor (C5aR) in various organs. In the mouse and rat models of sepsis (cecal ligation and puncture, CLP), C5a blockade by anti-C5a antibody, anti-C5aR antibody or use of a C5aR antagonist (C5aRa) significantly improved survival in CLP animals. C5a blockade in sepsis attenuated the systemic inflammatory response syndrome (SIRS) by reducing plasma levels of IL-6 and decreasing bacteria counts in blood and organs. Anti-C5a treatment in CLP rodents markedly attenuated sepsis-induced defects in the coagulation/fibrinolytic system, while liver and kidney functions were remarkably preserved in contrast to CLP animals not receiving anti-C5a in which multi-organ failure occurs. In CLP rats treated with anti-C5a, thymus atrophy was diminished and thymocyte apoptosis was inhibited. Defective neutrophil functions (chemotaxis, phagocytosis, respiratory burst) caused by sepsis were significantly improved in CLP rats treated with anti-C5a. These data suggest during CLP-induced sepsis C5a has very harmful consequences and that its blockade might be a promising therapeutic strategy for the treatment of humans with sepsis. This review will summarize the beneficial effects of anti-C5a treatment in the rodent model of sepsis and will introduce the most recent patents on this line of research.

PubMed Disclaimer

Cited by

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults.
Chen G, Li N, Dai X, Tu S, Shen Z, Wu K, Jin T, Wu J, Peng C, Sheng G, Zhu M, Tang L, Li L. Chen G, et al. Infect Dis Ther. 2023 Feb;12(2):663-675. doi: 10.1007/s40121-023-00759-4. Epub 2023 Jan 25. Infect Dis Ther. 2023. PMID: 36697937 Free PMC article.
Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients.
Ahmad FM, A Al-Binni M, Bani Hani A, Abu Abeeleh M, Abu-Humaidan AHA. Ahmad FM, et al. J Inflamm Res. 2022 Jan 8;15:153-162. doi: 10.2147/JIR.S344282. eCollection 2022. J Inflamm Res. 2022. PMID: 35046691 Free PMC article.
Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).
Bauer M, Weyland A, Marx G, Bloos F, Weber S, Weiler N, Kluge S, Diers A, Simon TP, Lautenschläger I, Gründling M, Jaschinski U, Simon P, Nierhaus A, Moerer O, Reill L, Jörres A, Guo R, Loeffler M, Reinhart K, Riedemann N. Bauer M, et al. Crit Care Explor. 2021 Nov 17;3(11):e0577. doi: 10.1097/CCE.0000000000000577. eCollection 2021 Nov. Crit Care Explor. 2021. PMID: 34806021 Free PMC article.
Endothelial microvesicles carrying Src-rich cargo impair adherens junction integrity and cytoskeleton homeostasis.
Chatterjee V, Yang X, Ma Y, Cha B, Meegan JE, Wu M, Yuan SY. Chatterjee V, et al. Cardiovasc Res. 2020 Jul 1;116(8):1525-1538. doi: 10.1093/cvr/cvz238. Cardiovasc Res. 2020. PMID: 31504252 Free PMC article.
Renal protective effects of zingerone in a mouse model of sepsis.
Lee BS, Lee C, Yang S, Ku SK, Bae JS. Lee BS, et al. BMB Rep. 2019 Apr;52(4):271-276. doi: 10.5483/BMBRep.2019.52.4.175. BMB Rep. 2019. PMID: 30158024 Free PMC article.

C5a, a therapeutic target in sepsis - PubMed (original) (raw)